Navigating the Transition from 21 CFR 212 to 210/211 Compliance in Radiopharmaceutical Manufacturing
• Key differences and gaps between 21 CFR 212 and 210/211
• Impact on CDMO/CMO facilities
• Considerations for radiopharmacies and compounding pharmacies